1400 related articles for article (PubMed ID: 26729443)
21. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
22. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
23. High MET receptor expression but not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer.
Feng Y; Minca EC; Lanigan C; Liu A; Zhang W; Yin L; Pennell NA; Farver C; Tubbs R; Ma PC
J Thorac Oncol; 2014 May; 9(5):646-53. PubMed ID: 24722154
[TBL] [Abstract][Full Text] [Related]
24. Capmatinib in
Wolf J; Seto T; Han JY; Reguart N; Garon EB; Groen HJM; Tan DSW; Hida T; de Jonge M; Orlov SV; Smit EF; Souquet PJ; Vansteenkiste J; Hochmair M; Felip E; Nishio M; Thomas M; Ohashi K; Toyozawa R; Overbeck TR; de Marinis F; Kim TM; Laack E; Robeva A; Le Mouhaer S; Waldron-Lynch M; Sankaran B; Balbin OA; Cui X; Giovannini M; Akimov M; Heist RS;
N Engl J Med; 2020 Sep; 383(10):944-957. PubMed ID: 32877583
[TBL] [Abstract][Full Text] [Related]
25. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K
Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
[TBL] [Abstract][Full Text] [Related]
27. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
Xia Y; Jin R; Li M; Lan F; Zhu H; Yu Y; Miao D; Wang Q; Zhou Y; Selvaggi G; Ying S; Zhang J; Shen H; Le X; Li W
Cancer Lett; 2023 May; 561():216140. PubMed ID: 36948240
[TBL] [Abstract][Full Text] [Related]
28. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
[TBL] [Abstract][Full Text] [Related]
29. Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 cases.
Mayenga M; Assié JB; Monnet I; Massiani MA; Tabeze L; Friard S; Fraboulet S; Métivier AC; Chouaïd C; Zemoura L; Longchampt E; Callens C; Melaabi S; Couderc LJ; Doubre H
Lung Cancer; 2020 Dec; 150():21-25. PubMed ID: 33045465
[TBL] [Abstract][Full Text] [Related]
30. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
31. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
32. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations.
Chatziandreou I; Tsioli P; Sakellariou S; Mourkioti I; Giannopoulou I; Levidou G; Korkolopoulou P; Patsouris E; Saetta AA
PLoS One; 2015; 10(7):e0133859. PubMed ID: 26208325
[TBL] [Abstract][Full Text] [Related]
34. Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.
Jin W; Shan B; Liu H; Zhou S; Li W; Pan J; Lin L; Hu D; Pan Y
J Thorac Oncol; 2019 Jul; 14(7):e137-e139. PubMed ID: 31055074
[No Abstract] [Full Text] [Related]
35. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
[TBL] [Abstract][Full Text] [Related]
36. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
Fischer A; Bankel L; Hiltbrunner S; Rechsteiner M; Rüschoff JH; Rushing EJ; Britschgi C; Curioni-Fontecedro A
Target Oncol; 2022 Nov; 17(6):683-694. PubMed ID: 36136211
[TBL] [Abstract][Full Text] [Related]
37. Amplification of Wild-type
Bahcall M; Awad MM; Sholl LM; Wilson FH; Xu M; Wang S; Palakurthi S; Choi J; Ivanova EV; Leonardi GC; Ulrich BC; Paweletz CP; Kirschmeier PT; Watanabe M; Baba H; Nishino M; Nagy RJ; Lanman RB; Capelletti M; Chambers ES; Redig AJ; VanderLaan PA; Costa DB; Imamura Y; Jänne PA
Clin Cancer Res; 2018 Dec; 24(23):5963-5976. PubMed ID: 30072474
[TBL] [Abstract][Full Text] [Related]
38. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers.
Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A
Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371
[TBL] [Abstract][Full Text] [Related]
39. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
[TBL] [Abstract][Full Text] [Related]
40. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring
Engstrom LD; Aranda R; Lee M; Tovar EA; Essenburg CJ; Madaj Z; Chiang H; Briere D; Hallin J; Lopez-Casas PP; Baños N; Menendez C; Hidalgo M; Tassell V; Chao R; Chudova DI; Lanman RB; Olson P; Bazhenova L; Patel SP; Graveel C; Nishino M; Shapiro GI; Peled N; Awad MM; Jänne PA; Christensen JG
Clin Cancer Res; 2017 Nov; 23(21):6661-6672. PubMed ID: 28765324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
